Karam Mounzer, Ricky K Hsu, Jennifer Fusco, Anthony Mills, Kevin R Frost, Gerald Pierone, Michael Sension, Philip C Lackey, Adrienne Guignard, Bryn Jones, Annemiek de Ruiter, Vani Vannappagari, Gregory P. Fusco Late Breaker ID week: Low Rate of HIV Acquisition on Cabotegravir Pre-Exposure Prophylaxis in OPERA: Possible Long-Acting Early Viral Inhibition Observed , ID Week 2026: 2026
Gerald Pierone, Jr., 1Michael D. Osterman, 2Rachel Palmieri Weber, 2Karam Mounzer, 3Ricky K. Hsu, 4Jennifer S. Fusco, 2Cassidy E. Henegar, 5Michelle Kisare, 6Piotr Budnik, 6Vani Vannappagari, 5Gregory P. Fusco Virologic Outcomes of Individuals Prescribed Dolutegravir/Lamivudine After an Oral Antiretroviral Therapy Treatment Interruption: Findings from the OPERA Cohort , ID Week 2026: 2026
Aimee A. Metzner,1 Heidi Swygard,1 William Valenti,2 Karam Mounzer,3 Roberto Ortiz,4 Diana Garbinsky,5 Kimberly Boyle,5 Maria Reynolds,5 David Richardson,5 Robert Morris,1 Meg Sullivan1 (P - 932) User Experience Concepts Assessed Among People in the United States Using Long-Acting Injectable Cabotegravir for PrEP in Real-World Care: Results from the CAPTIVATE Study , ID Week 2026: 2026
Elion R, Henegar C, McEwen I, Frick A, Ramgopal M, Santiago S, Mounzer K, Huhn G, Walworth C, Ragone L, Vannappagari V. Real-world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research Network , HIV Med: 2026
Azzoni L, Zhang L, Zhu K, Fair M, Hiserodt E, Mounzer K, Wallin JJ, Montaner LJ, Cai Y. Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorder , Front Mol Biosci, 13: 2026,1728953
Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial , Lancet, 407: 2026,1249-1258
Isobel McEwen1 , Gayathri Sridhar2 , Richard Elion1 , Leigh Ragone3 , Annemiek De Ruiter2 , Michael Aboud2 , Jean van Wyk4 , Kenneth Mayer5 , Karam Mounzer6 , Moti N. Ramgopal7 , Vani Vannappagari2 Long-Term Use, HIV Testing & Effectiveness in Individuals on CAB LA PrEP in the Trio Health Cohort , CROI 2026: 2026
Dieterich DT, Brunet L, Hsu RK, Mounzer K, Pierone G Jr, Wohlfeiler MB, Fusco JS, Dunbar MS, Gruber J, Yee LJ, Frenette C, Lim T, Fusco GP. . Monitoring and risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B. , AIDS: 2026
Jessica Altamirano1, Karam Mounzer2, Brooke Levis3, Cindy Markarian4, Courtney Sherman5, Laura Armas6, Quateka Cochran7, Mona-Gekanju Toeque4, Gayathri Sridhar8, Vani Vannappagari8, Kimberley Brown8, Laurence Brunet3, Jennifer S. Fusco3 "Resuppression and resistance after confirmed virologic failure among women on CAB+RPV LA in the OPERA Cohort” , AIDS: 2026
Mounzer K, Brunet L, Hsu RK, Lackey PC, Sension MG, Wohlfeiler MB, Dunn K, Fusco JS, Fusco GP. Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment Outcomes , AIDS Patient Care STDS: 2026
